Caliway Biopharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Yufang Ling

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	11.1%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Companies Like Caliway Biopharmaceuticals (TWSE:6919) Can Afford To Invest In Growth

Oct 02

CEO

Yufang Ling

no data

Tenure

Ms. Yufang Ling serves as CEO and R&D Chief of Caliway Biopharmaceuticals Co. Ltd. She holds a master's degree from the Institute of Biochemistry and Molecular Biology, National Cheng Kung University Schoo...

Caliway Biopharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

Recent updates

Companies Like Caliway Biopharmaceuticals (TWSE:6919) Can Afford To Invest In Growth

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Second quarter 2024 earnings released: NT$1.27 loss per share (vs NT$1.35 loss in 2Q 2023)

New major risk - Share price stability

First quarter 2024 earnings released: NT$1.57 loss per share (vs NT$1.06 loss in 1Q 2023)

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

New minor risk - Share price stability

Full year 2023 earnings released: NT$3.94 loss per share (vs NT$4.89 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease

Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

New major risk - Revenue and earnings growth

Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease

Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding

Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7

First half 2023 earnings released

Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

CEO

Tenure